Skip to main content

Arcutis Biotherapeutics Inc

For the period ended Dec 31, 2023. Filed Feb 27, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 27, 2024

ARQT$26.20+2.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

ARCUTIS BIOTHERAPEUTICS, INC.
Date:February 27, 2024By:/s/ Todd Franklin Watanabe
Todd Franklin WatanabePresident, Chief Executive Officer and Director(Principal Executive Officer)
Date:February 27, 2024By:/s/ John W. Smither
John W. SmitherChief Financial Officer(Principal Financial and Accounting Officer)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Todd Franklin Watanabe, John W. Smither and Mas Matsuda, his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or their, his or her substitutes or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Todd Franklin WatanabePresident, Chief Executive Officer and Director(Principal Executive Officer)February 27, 2024
Todd Franklin Watanabe
/s/ John W. SmitherChief Financial Officer(Principal Accounting and Financial Officer)February 27, 2024
John W. Smither
/s/ Patrick J. HeronDirector, ChairmanFebruary 27, 2024
Patrick J. Heron
/s/ Bhaskar ChaudhuriDirectorFebruary 27, 2024
Bhaskar Chaudhuri, Ph.D.
/s/ Terrie CurranDirectorFebruary 27, 2024
Terrie Curran
/s/ Halley E. GilbertDirectorFebruary 27, 2024
Halley E. Gilbert
/s/ Keith R. LeonardDirectorFebruary 27, 2024
Keith R. Leonard
/s/ Sue-Jean LinDirectorFebruary 27, 2024
Sue-Jean Lin
/s/ Howard G. WelgusDirectorFebruary 27, 2024
Howard G. Welgus, M.D.
/s/ Neha KrishnamohanDirectorFebruary 27, 2024
Neha Krishnamohan
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.